Celgene (CELG) PT Set at $152.00 by Guggenheim

Celgene (NASDAQ:CELG) has been assigned a $152.00 target price by investment analysts at Guggenheim in a research report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim’s price target points to a potential upside of 42.95% from the stock’s previous close.

A number of other research analysts have also commented on CELG. Morgan Stanley lowered Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 price target for the company. in a report on Thursday, October 5th. BTIG Research reiterated a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reiterated a “hold” rating and set a $112.00 price target on shares of Celgene in a report on Monday, October 30th. Vetr upgraded Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 price target for the company in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 price target on Celgene and gave the stock a “buy” rating in a report on Thursday, November 16th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating, twenty-one have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $134.92.

Shares of Celgene (NASDAQ CELG) traded down $1.55 during midday trading on Monday, hitting $106.33. The company had a trading volume of 9,611,900 shares, compared to its average volume of 4,833,915. The company has a market cap of $83,720.00, a PE ratio of 25.08, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. Celgene has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The business had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same quarter in the previous year, the business posted $1.58 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. analysts predict that Celgene will post 6.68 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Capital Counsel LLC NY grew its holdings in Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC grew its holdings in Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock worth $250,000 after acquiring an additional 11 shares in the last quarter. Flagship Harbor Advisors LLC boosted its holdings in shares of Celgene by 0.9% in the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 18 shares in the last quarter. Savant Capital LLC boosted its holdings in shares of Celgene by 0.9% in the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after buying an additional 20 shares in the last quarter. Finally, TCI Wealth Advisors Inc. boosted its holdings in shares of Celgene by 0.9% in the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 26 shares in the last quarter. 79.74% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Celgene (CELG) PT Set at $152.00 by Guggenheim” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/12/26/celgene-celg-pt-set-at-152-00-by-guggenheim.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit